Dual anti-HER2 therapy has improved the outcomes of HER2-positive breast cancer patients, but at the same time, it may increase the risk of treatment-induced cardiotoxicity to some extent (Swain et al., 2020; Huang et al., 2022). Here, ERBB2 is linked to breast cancer.